Warren, Wyden, Senate Democrats Introduce Bill to Force Disclosure of TrumpRx Terms with Big Pharma

Warren, Wyden, Senate Democrats Introduce Bill to Force Disclosure of TrumpRx Terms with Big Pharma

Bill Text (PDF) | Text of One Pager (PDF)

Washington, D.C. - U.S. Senator Elizabeth Warren (D-Mass.), a member of the Senate Finance Committee; Ron Wyden (D-Ore.), Ranking Member of the Senate Finance Committee; and 18 Senate Democrats introduced new legislation to force the Trump administration to disclose the terms of deals signed with more than a dozen of the largest pharmaceutical companies and conduct an independent analysis to determine whether American families will see lower prices from the deals.

The Drug Deal Disclosure Act requires the Department of Health and Human Services (HHS) to release the details of the deals struck between drug manufacturers and the Trump Administration, including all documentation associated with the agreements, and instructs the Congressional Budget Office and the Government Accountability Office to co-author and publish a comprehensive analysis of the economic and budgetary impacts of all disclosed agreements so that the American people can confidently assess the extent to which these deals save patients and taxpayers money.

The Drug Deal Disclosure Act cosponsors include Senators Peter Welch (D-Vt.), Ruben Gallego (D-Ariz.), Jeff Merkley (D-Ore.), Ben Ray Luján (D-N.M.), Tammy Baldwin (D-Wis.), Sheldon Whitehouse (D-R.I.), Mark Kelly (D-Ariz.), Bernie Sanders (I-Vt.), Mark Warner (D-Va.), Tina Smith (D-Minn.), Maggie Hassan (D-N.H.), Catherine Cortez Masto (D-Nev.), Michael Bennet (D-Colo.), Raphael Warnock (D-Ga.), Mazie Hirono (D-Hawaii), Maria Cantwell (D-Wash.), and Chris Van Hollen (D-Md.).

Absent further transparency, Trump's drug deals are a sham that benefits pharmaceutical corporations while offering little to no savings to patients and their families. Any potential savings for state Medicaid programs are unknown and likely to be minimal, and there is no evidence that companies will lower launch prices for their drugs. Meanwhile, drug companies that inked these deals report that they are receiving tariff relief, exemption from Trump's other half-baked Medicare initiatives designed to create price parity with other nations, and Priority Review Vouchers to get their products approved by the Food and Drug Administration (FDA) faster.

Warren has led the effort to spotlight Trump's smoke and mirrors when it comes to lower drug prices. She pressed every company that reached these so-called deals to disclose how the agreements will benefit the company and how they will lower costs for taxpayers and families.

###